
A recent meta-analysis of four randomized clinical trials has found that Venoarterial extracorporeal membrane oxygenation (VA-ECMO) does not significantly reduce the 30-day death rate in patients with infarct-related cardiogenic shock when compared to optimal medical therapy alone. The study, which analyzed data from 567 patients, also revealed higher complication rates with VA-ECMO, including major bleeding and peripheral vascular issues. This research suggests a need for careful consideration when using VA-ECMO in such cases, highlighting the lack of a survival benefit and potential risks associated with the treatment.
Like
Save
Share